Xiantao Zhang

Guangzhou, 510080, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Ferritin nanoparticle-based vaccine enhances mucosal immunity by promoting antigen uptake and activation of alveolar macrophages.

Ferritin nanoparticle-based vaccine enhances mucosal immunity by promoting antigen uptake and activation of alveolar macrophages.

Journal: Virologica Sinica
Published: April 14, 2026

A self-assembling ferritin nanoparticle-based trivalent vaccine of gB/gE/gH elicits potent immune responses against varicella-zoster virus.

A self-assembling ferritin nanoparticle-based trivalent vaccine of gB/gE/gH elicits potent immune responses against varicella-zoster virus.

Journal: International journal of biological macromolecules
Published: June 12, 2025

Development of T follicular helper cell-independent nanoparticle vaccines for SARS-CoV-2 or HIV-1 by targeting ICOSL.

Development of T follicular helper cell-independent nanoparticle vaccines for SARS-CoV-2 or HIV-1 by targeting ICOSL.

Journal: NPJ vaccines
Published: February 25, 2024

The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis.

The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis.

Journal: Nature immunology
Published: April 17, 2023

A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 Sublineages.

A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 Sublineages.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: February 14, 2023

SARS-CoV-2 Omicron: a new challenge for pandemic and vaccine.

SARS-CoV-2 Omicron: a new challenge for pandemic and vaccine.

Journal: Signal transduction and targeted therapy
Published: May 30, 2022

SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance.

SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance.

Journal: Signal transduction and targeted therapy
Published: December 08, 2021

Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.

Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: November 23, 2021

Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route.

Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route.

Journal: Signal transduction and targeted therapy
Published: August 05, 2021

USP10 regulates B cell response to SARS-CoV-2 or HIV-1 nanoparticle vaccines through deubiquitinating AID.

USP10 regulates B cell response to SARS-CoV-2 or HIV-1 nanoparticle vaccines through deubiquitinating AID.

Journal: Signal transduction and targeted therapy
Published: July 26, 2021

CRL2KLHDC3 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression.

CRL2KLHDC3 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression.

Journal: Oncogene
Published: July 02, 2021

Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles.

Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles.

Journal: Cellular & molecular immunology
Published: May 29, 2021
Showing 1-12 of 16

Last Updated: 09/26/2026